Takeda

Fruzaqla (fruquintinib) is an oral kinase inhibitor from Takeda that selectively blocks VEGF receptors 1, 2 and 3. By cutting off tumour blood vessel formation it is used in metastatic colorectal cancer that has progressed through standard therapies.

Cancers need new blood vessels to grow and spread, and they build them by sending VEGF signals to vessel cells. Fruquintinib blocks the receptors that

Pantoprazole (Protonix) is a proton pump inhibitor that reduces the amount of acid the stomach makes. It heals erosive esophagitis from gastroesophageal reflux disease, keeps it healed, treats excess acid conditions such as Zollinger-Ellison syndrome, and relieves reflux symptoms.

Pantoprazole is a proton pump inhibitor. It is a weak base that crosses into the acidic compartment of the stomach's parietal cells, where it becomes

Iclusig (ponatinib) is an oral, multi-targeted kinase inhibitor from Takeda for Philadelphia chromosome-positive leukemias. It blocks the BCR-ABL driver protein in chronic myeloid leukemia and acute lymphoblastic leukemia, including the hard-to-treat T315I mutation, after other kinase inhibitors have failed or are unsuitable.

Chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia are driven by BCR-ABL, an abnormal tyrosine kinase that tel

Entyvio (vedolizumab) is a gut-selective integrin antagonist from Takeda for moderately to severely active ulcerative colitis and Crohn's disease in adults who have not responded adequately to conventional therapy or TNF-alpha antagonists. In the European Union it also covers chronic pouchitis after surgery for ulcerative colitis.

Vedolizumab is given by infusion or injection and blocks alpha4beta7 integrin, a docking protein that certain white blood cells use to enter the gut.